A phase ii study of combined hormonal and capecitabine as first line treatment in metastatic breast cancer / Noha Fouad M. Rashad ; Supervised Hussein Khaled , Thoraya Abdelhamid , Samia Shooman

By:

Noha Fouad Mohamed Rashad

Contributor(s):

Material type: Text

TextLanguage: English Publication details: Cairo : Noha Fouad Mohamed Rashad , 2018Description: 143 P. : charts , facsimiles ; 25cmOther title:

دراسه إكلينيكيه من المرحله الثانيه على استخدام العلاج الهرمونى مع عقار الكابسيتابين كعلاج أولى لحالات سرطان الثدى المنتشر [Added title page title]

Subject(s):

Available additional physical forms:

Issued also as CD

Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) Summary: Background: Preclinical studies have shown that the combination of tamoxifen and oral fluoropyrimidines in estrogen receptor (ER)-positive cell lines enhance antitumor efficacy. This prospective phase II study evaluated the safety and efficacy of combined chemo-endocrine treatment as first line in patients with metastatic breast cancer (MBC). Patients and methods: A prospective study has been conducted in NCI (National Cancer Institute) medical oncology department in outpatient setting, in the period between September 2014 and April 2016. The study included 40 patients with pathologically proven advanced breast cancer with ER +ve, Her2 -ve treated with either tamoxifen/capecitabine or letrozole/capecitabine as first line treatment for metastatic breast cancer. Thymidine phosphorylase enzyme (TP) serum level was measured before starting treatment and after one month of treatment. Serum tamoxifen, hydroxytamoxifen and 5FU levels were measured in patients receiving tamoxifen/capecitabine after one month of starting treatment. The primary end point was progression free survival (PFS), while the secondary end points were overall response rate (ORR), overall survival (OS) and incidence of adverse events as a measure of safety

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Copy number	Status	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2018.No.P (Browse shelf(Opens below))		Not for loan	01010110076905000
CD - Rom	مخـــزن الرســائل الجـــامعية - البدروم	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2018.No.P (Browse shelf(Opens below))	76905.CD	Not for loan	01020110076905000

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical)

Background: Preclinical studies have shown that the combination of tamoxifen and oral fluoropyrimidines in estrogen receptor (ER)-positive cell lines enhance antitumor efficacy. This prospective phase II study evaluated the safety and efficacy of combined chemo-endocrine treatment as first line in patients with metastatic breast cancer (MBC). Patients and methods: A prospective study has been conducted in NCI (National Cancer Institute) medical oncology department in outpatient setting, in the period between September 2014 and April 2016. The study included 40 patients with pathologically proven advanced breast cancer with ER +ve, Her2 -ve treated with either tamoxifen/capecitabine or letrozole/capecitabine as first line treatment for metastatic breast cancer. Thymidine phosphorylase enzyme (TP) serum level was measured before starting treatment and after one month of treatment. Serum tamoxifen, hydroxytamoxifen and 5FU levels were measured in patients receiving tamoxifen/capecitabine after one month of starting treatment. The primary end point was progression free survival (PFS), while the secondary end points were overall response rate (ORR), overall survival (OS) and incidence of adverse events as a measure of safety

Issued also as CD

There are no comments on this title.

to post a comment.